Nu Skin Enterprises (NUS)
(Real Time Quote from BATS)
$6.44 USD
+0.04 (0.63%)
Updated Oct 8, 2024 03:55 PM ET
After-Market: $6.44 0.00 (0.00%) 4:14 PM ET
5-Strong Sell of 5 5
A Value B Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$6.44 USD
+0.04 (0.63%)
Updated Oct 8, 2024 03:55 PM ET
After-Market: $6.44 0.00 (0.00%) 4:14 PM ET
5-Strong Sell of 5 5
A Value B Growth A Momentum A VGM
Zacks News
NUS Stock Trading Below 200 & 50-Day SMA: What Should You Do Now?
by Zacks Equity Research
Nu Skin is encountering persistent macroeconomic obstacles, weighing on consumer spending and customer acquisition.
Nu Skin Trading Near 52-Week Low: Should You Buy or Sell NUS Stock?
by Zacks Equity Research
Nu Skin is facing macroeconomic difficulties and a slow-moving direct-selling market. Foreign currency headwinds are also weighing on NUS.
NUS Stock Hurt by Customer Acquisition Challenges: How to Play Ahead?
by Zacks Equity Research
Nu Skin encounters macroeconomic challenges related to volatile consumer spending and strong currency headwinds.
Nu Skin (NUS) Down 28% in 3 Months: What's the Next Best Move?
by Zacks Equity Research
Nu Skin (NUS) has been battling persistent macroeconomic headwinds, which have been weighing on consumer spending and customer acquisition. Strong currency headwinds are also playing foul.
Are Options Traders Betting on a Big Move in Nu Skin (NUS) Stock?
by Zacks Equity Research
Investors need to pay close attention to Nu Skin (NUS) stock based on the movements in the options market lately.
Nu Skin (NUS) Trims FY24 View Despite Q2 Earnings Beat
by Zacks Equity Research
Nu Skin's (NUS) second-quarter 2024 results reflect lower earnings and net sales amid a dynamic macro-environment. Management lowers the 2024 guidance range.
Nu Skin Enterprises (NUS) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Nu Skin (NUS) delivered earnings and revenue surprises of 16.67% and 2.11%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Nu Skin (NUS) Set to Report Q2 Earnings: What to Expect?
by Zacks Equity Research
Nu Skin's (NUS) Q2 results are likely to reflect the impacts of macroeconomic challenges, including inflation and adverse currency fluctuations.
Nu Skin (NUS) Navigates a Tough Landscape on Growth Strategies
by Zacks Equity Research
Nu Skin (NUS) has been dealing with challenges related to customer and affiliate acquisition. However, product launches, technological advancements and strength in the Rhyz business bode well.
Nu Skin (NUS) Troubled by Customer Acquisition Challenges
by Zacks Equity Research
Nu Skin (NUS) has been battling persistent macroeconomic headwinds across most regions, which has affected customer and affiliate acquisition.
Nu Skin (NUS) Up 5.6% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Nu Skin (NUS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Nu Skin (NUS) Q1 Earnings Beat, Revenues Hurt by Currency Woes
by Zacks Equity Research
Nu Skin's (NUS) first-quarter 2024 results reflect challenges related to volatile currency movements, while cost-management efforts work well.
Nu Skin Enterprises (NUS) Surpasses Q1 Earnings Estimates
by Zacks Equity Research
Nu Skin (NUS) delivered earnings and revenue surprises of 80% and 3.09%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
Nu Skin (NUS) Q1 Earnings Coming Up: Factors to Consider
by Zacks Equity Research
Nu Skin's (NUS) first-quarter 2024 earnings will likely reflect the adverse impact of macroeconomic challenges like a slowdown in consumer spending. Unfavorable currency translations are a concern.
Is Invesco High Yield Equity Dividend Achievers ETF (PEY) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PEY
Why Is Inter Parfums (IPAR) Down 4.1% Since Last Earnings Report?
by Zacks Equity Research
Inter Parfums (IPAR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Nu Skin (NUS) Down 7.2% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Nu Skin (NUS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Nu Skin (NUS) Down More Than 25% in 3 Months: Here's Why
by Zacks Equity Research
Nu Skin (NUS) is battling macroeconomic challenges, with inflation putting pressure on consumer spending and customer acquisition. Management expects revenues to decline in 2024.
Nu Skin (NUS) Q4 Earnings Top Estimates, Revenues Decline Y/Y
by Zacks Equity Research
Nu Skin's (NUS) fourth-quarter 2023 results reflect the persistence of macroeconomic challenges and hurdles related to business transformation, offset by growth in some regions.
Nu Skin Enterprises (NUS) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Nu Skin (NUS) delivered earnings and revenue surprises of 27.59% and 1.94%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Things to Consider Ahead of Nu Skin's (NUS) Q4 Earnings
by Zacks Equity Research
Nu Skin's (NUS) fourth-quarter 2023 earnings will likely reflect the adverse impact of macroeconomic challenges like a slowdown in consumer spending. Unfavorable currency translations pose concerns.
Philip Morris (PM) Lags Q4 Earnings Estimates
by Zacks Equity Research
Philip Morris (PM) delivered earnings and revenue surprises of -5.56% and 0.98%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Nu Skin Enterprises (NUS) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Nu Skin (NUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is Invesco High Yield Equity Dividend Achievers ETF (PEY) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for PEY
Product Launches Aid Nu Skin (NUS), Macroeconomic Hurdles Ail
by Zacks Equity Research
Nu Skin (NUS) is benefiting from the Nu Vision 2025 strategy driven by a dynamic affiliate opportunity platform. However, escalating macroeconomic pressures are hampering key markets.